Process for the production of levetiracetam

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

View original document View source feed page

What changed

USPTO issued Patent No. US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. on March 31, 2026, covering a novel process for producing levetiracetam through crystallization in an aqueous solution, optionally with a water-soluble solvent. The process yields levetiracetam with no residual organic solvent. The application (No. 18210330) was filed on June 15, 2023, and the patent contains 13 claims classified under C07D 207/27.

Pharmaceutical manufacturers and generic drug producers should review this patent to ensure their levetiracetam production processes do not infringe on the granted claims. This is an informational patent grant conferring exclusivity rights to the assignee; no compliance actions or deadlines are triggered by this notice.

Source document (simplified)

← USPTO Patent Grants

Process for the production of levetiracetam

Grant US12590059B2 Kind: B2 Mar 31, 2026

Assignee

SUZHOU BRIGHTHOPE PHARMATECH CO., LTD

Inventors

Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song

Abstract

There is disclosed a process for the production of levetiracetam by crystallizing levetiracetam in an aqueous solution, optionally in the presence of a water-soluble solvent. The product of levetiracetam contains no residual organic solvent.